Propionic Acidemia: Can mRNA Replace a Missing Enzyme?

Why are researchers testing mRNA for propionic acidemia?

IndexBox's forecast for nucleic acid raw materials through 2035 highlights demand from medicines built around genetic instructions. A clinically distinct application is enzyme replacement through mRNA: helping cells manufacture a protein needed for metabolism. The forecast provides an industry backdrop; evidence that a particular treatment helps patients must come from clinical research. [IndexBox market forecast](https://www.indexbox.io/blog/nucleic-acid-raw-materials-market-forecast-to-2035-growth-accelerates-on-mrna-vaccine-and-gene-therapy-demand/).

Propionic acidemia is an inherited disorder that disrupts the processing of certain protein and fat components. Variants in PCCA or PCCB impair an enzyme called propionyl-CoA carboxylase, allowing harmful compounds to accumulate. Symptoms often begin shortly after birth and can include vomiting, poor feeding and lethargy; severe illness can involve seizures or coma. In later-onset disease, infection or fasting can trigger deterioration. [MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/propionic-acidemia/).

The investigational medicine mRNA-3927 contains two mRNAs encoding the enzyme's PCCA and PCCB subunits. Its intended effect is intracellular protein replacement. [Published clinical study](https://www.nature.com/articles/s41586-024-07266-7).

What did the early mRNA-3927 clinical trial show?

The interim phase 1/2 report published in Nature in 2024 included 16 participants, using data through May 2023. Among eight participants who had experienced metabolic decompensation during the preceding year, researchers estimated a 70% reduction in event risk during treatment. These were historical comparisons within participants, without a randomized control group. [Nature trial report](https://www.nature.com/articles/s41586-024-07266-7).

No dose-limiting toxicities occurred in that analysis, but infusion reactions occurred and one participant withdrew because of a reaction. Small numbers, an open-label design and unequal observation periods limit interpretation. The findings support further investigation rather than a conclusion that benefits or long-term safety are established. [Trial findings and limitations](https://www.nature.com/articles/s41586-024-07266-7).

What does commercial investment mean for future treatment access?

On January 29, 2026, Moderna announced a collaboration with Recordati to advance mRNA-3927 through the final stages of clinical development and support worldwide commercialization if approved. That announcement documents a development partnership, not a regulatory approval or a new efficacy result. The company explicitly described commercialization as conditional on approval. [Moderna's partnership announcement](https://www.modernatx.com/en-US/media-center/all-media/blogs/recordati-collaboration-globally-commercialize-investigational-propionic-acidemia-therapy).

For families, the practical questions concern whether treatment reduces serious metabolic crises, how burdensome repeated administration becomes, and how benefits compare with adverse effects over time. Our interpretation is that growing investment makes these clinical questions more consequential, without resolving them. A raw-materials forecast cannot establish a treatment's effectiveness, price, insurance coverage or availability date; those require separate evidence and decisions.